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Abstract 
Background: There is a scarcity of studies addressing the factors associated with impaired 
fasting glucose in Chinese patients with uncomplicated hypertension. We included 1,218 
patients newly prescribed a single antihypertensive drug in the public primary healthcare 
setting in Hong Kong, where their fasting glucose levels were measured 6-7 weeks after the 
first-ever antihypertensive prescription.     
Methods: The odds ratios of having above borderline (> 6.1 mmol/l) and adverse (> 7.0 
mmol/l) glucose levels, respectively, were studied according to patient age, gender, 
socioeconomic status, clinic types and antihypertensive drug classes by multivariable 
regression analyses.   
Results: The fasting glucose levels were statistically similar (p=0.786) among patients 
prescribed thiazide diuretics (5.48mmol/l, 95%, 5.38, 5.59), calcium channel blockers (5.46 
mmol/l, 95% C.I. 5.37, 5.54), β-blockers (5.42 mmol/l, 95% C.I. 5.34, 5.51) and drugs acting 
on the renin angiotensin system (RAS) [5.41 mmol/l, 95% C.I. 5.20, 5.61].  Multivariate 
analyses reported no significant associations between antihypertensive drug class and 
impaired fasting glucose.  Elderly patients and male gender were significantly more likely to 
present with above borderline and adverse readings respectively.  Clinicians should be aware 
of the increased risk of impaired fasting glucose in these groups, and use of thiazides should 
not in itself deter its use as a first-line antihypertensive agent among ethnic Chinese patients.  
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Background  
Hypertension was estimated to be present in at least 73% of citizens in the United States who 
have diabetes [1].  Many people were diagnosed with hypertension prior to diabetes [2], and 
a significant number of hypertensive patients have diabetes gone unrecognized [3].  Diabetes 
was reported to impose a two-fold or greater risk for cardiovascular morbidity and mortality 
[4] and together with hypertension this risk increased dramatically [5].  The co-existence of 
diabetes and hypertension are associated with greater degrees of arterial stiffness [6] which 
leads to earlier rises in systolic and pulse pressures [7]. 
 
The importance of early detection of diabetes among hypertensive patients has been 
highlighted in the guidelines of the American Diabetes Association [8] and the seventh report 
of the Joint National Committee [9], which called for screening for diabetes at the time of 
diagnosing hypertension and repeating screening annually. 
 
There has been evidence that thiazide diuretics could precipitate overt diabetes [10] and it 
was well recognized in authoritative medical textbooks [11] that diuretics are 
"contraindications" in prescribing for maturity-onset diabetic patients.  However, recent 
debate arose as to the best first-line antihypertensive in diabetic patients. For instance, 
diuretics were labeled as the least expensive and most effective agent, and "... should be the 
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first line treatment almost everyone with hypertension, including patients with diabetes..." 
[12]. In addition, studies on the relationship between antihypertensive drug classes and 
hyperglycemia among ethnic Chinese patients were scarce.  Local surveys among Chinese 
doctors reported that the majority chose thiazide diuretics as the best first-line agent for 
patients newly diagnosed with uncomplicated hypertension [13] but most changed their 
choice to Angiotensin Converting Enzyme inhibitors when diabetes was co-existing [14] due 
to physicians’ concerns that impaired fasting glucose could be a significant side effect of 
thiazide diuretics.  To our knowledge there have been no studies evaluating the association 
of various antihypertensive drug classes with the development of impaired fasting glucose or 
diabetes among ethnic Chinese patients. 
 
The present study examined the factors associated with elevated fasting glucose in Chinese 
patients with uncomplicated hypertension newly prescribed a single antihypertensive 
prescription. 
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Methods 
Data source 
The Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority, Hong 
Kong consists of all patient records in public, primary health sector visits since 2000. It 
captures patients’ demographics, clinical information including diagnoses, prescription details 
and laboratory investigation results in every out-patient consultation. One of the major 
functions of CDARS is research [15].  It is the single portal of information entry for all 
physicians practicing in the public sector in Hong Kong, and is a comprehensive record which 
allows cross-referencing when patients visit a different clinic in the public health sector.  
Also, it is the policy of all public clinics in Hong Kong to have their drug prescription details 
doubly checked by pharmacist professionals and any amendments were also recorded in the 
electronic patient record.  In addition to these good practices this database has been 
evaluated and found a high level of completeness with respect to demographic data (100%) 
and prescription details (99.98%) [16].   The present study included populations residing in 
the New Territory East Cluster (NTEC) of Hong Kong, which has a population of around 1.3 
million.  This cluster is further divided into 3 separate regions, namely Shatin, Tai-Po and 
the North District, from the most urbanized to the most rural regions respectively.  Their 
median monthly household incomes in 2006 were US$2,510, US$2,338 and US$2,078 for 
these three regions respectively, compared to the Hong Kong-wide figure of US$2,240.  
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These three regions have similar median ages (38-39 years), comparable with the median age 
of 39 years for Hong Kong [17].  This study gained approval from the Survey and 
Behavioural Research Ethics Committee, Chinese University of Hong Kong. 
 
Subjects 
Patients newly attended the public primary care practice, coded by physicians with 
International Classification of Primary Care (ICPC) K86 [uncomplicated hypertension] and 
who were prescribed at least one antihypertensive agent as the first-ever antihypertensive 
pharmacotherapy in the public sector during the study period of January 2004 to June 2007 
were included. Only patients who had their fasting glucose levels checked 4 to 16 weeks after 
the first-ever antihypertensive prescription were included.  Exclusion criteria included 
subjects having concomitant cardiovascular factors or clinical conditions which could 
confound the prescription choice of antihypertensive drugs, identified by the respective ICPC 
codes as follows: complicated hypertension (K87), diabetes mellitus (T90), impaired glucose 
tolerance (T91), gout (T92), lipid disorder (T93), stroke and cerebrovascular accident (K90 
and K91), ischemic heart diseases (K74, K76), acute myocardial infarction (K75), heart 
failure and heart diseases (K77, K84, K99), chronic obstructive pulmonary diseases, asthma 
(R79, R95, R96), and urological conditions (U14, U88, Y85, U78, Y79).  Also, patients 
discontinued or switched their drug prescription before fasting glucose was measured, or 
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prescribed at least one oral hypoglycemic agents or insulin preparations during the study 
period were excluded from the analysis. 
 
Each patient was classified into one drug group according to the antihypertensive drug class 
prescribed.  These include BBs, thiazide diuretics, Calcium Channel Blockers (CCBs), drugs 
acting on the rennin angiotensin system (RAS) and others (including α-blockers, 
potassium-sparing diuretics, vasodilators and combination therapy).   
 
Outcomes and Covariates 
The proportions of patients having desirable (< 6.0mmol/l), borderline (6.1-6.9mmol/l) and 
adverse (> 7.0mmol/l) levels of fasting glucose levels were compared among the various drug 
classes.  Plasma glucose from blood collected after an overnight fast of 8 to 12 hours was 
assayed enzymatically with commercial reagents (Abbott Laboratory Limited).  Independent 
predictors and covariates of elevated fasting glucose levels include patient age, gender, 
patients’ payment status (fee waivers vs. payers; each consultation costs US$5.77 including 
prescription and investigation fees), district of residence, type of clinics attended, namely 
General Out Patient Clinics (GOPCs), Family Medicine Specialist Clinics (FMSCs) and Staff 
Clinics (SCs), and the antihypertensive drug classes prescribed (thiazide diuretics, BB, CCB, 
RAS).   
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Statistical Analysis 
All the data were entered into the Statistical Package for Social Sciences (SPSS) version 13.0.  
A descriptive analysis was performed and the proportions of patients having desirable, 
borderline and adverse lipid results were compared by χ2 tests of homogeneity.  Student’s 
t-tests were used to compare continuous variables, except the time periods from 
antihypertensive prescription to blood measurement where Kruskal Wallis test was used for 
the skewed distribution.  The crude odds ratios of each drug class having above borderline (> 
6.1mmol/l) and adverse (> 7.0mmol/l) glucose readings were examined respectively using 
bivariate analysis.  This is followed by two separate unconditional binary logistic regression 
analyses for above borderline and adverse glucose readings using all the potential associated 
factors and covariates as independent variables.  The enter method was adopted as the 
regression selection procedure, and drug classes included thiazide diuretics, BB and CCB 
with RAS as a reference group.  All p values were two-sided, and p<0.05 were regarded as 
statistically significant. 
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Results  
Patient characteristics 
There were 1,218 eligible patients (Table 1).  Overall the mean age was 60.39 years (95% 
C.I. 59.67, 61.11 years), with females comprising 58.6% of the sample.   The median period 
between the first-ever antihypertensive drug prescription and checking of fasting glucose was 
7 weeks and these periods were statistically similar among all the drug groups (p=0.054) 
(Table 1). The average age of patients varied significantly across different drug groups 
(p<0.001), thought the size of the differences were relatively small (Table 1).  Gender 
differences according to the type of drug prescribed were also evident (p=0.008). 
Socio-economic status (with payment status as a proxy measure) of patients did not vary 
significantly across drug classes (p=0.415).  Most of them lived in more rural areas (29.6%, 
11.3%, 51.3% and 7.8% living in Shatin, Taipo, North district and other regions respectively), 
a finding which reflects that less affluent regions have higher proportion of patients suffering 
from uncomplicated hypertension only as the single disease entity without other clustering of 
cardiovascular (CVS) factors.  The most frequently attended clinics were GOPCs (86.5%), 
followed by FMSCs (10.1%) and staff clinics (3.4%), statistically different across 
antihypertensive drug classes (p<0.001). 
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Patterns of fasting glucose profiles by antihypertensive drug group 
The mean glucose levels of all patients were 5.49 mmol/l (95% C.I. 5.45, 5.53). Among the 
four drug classes, thiazide users had the highest absolute levels of fasting glucose (5.48 
mmol/l), followed by CCB (5.46 mmol/l), BB (5.42 mmol/l) and RAS (5.41 mmol/l).  
However these apparent differences in lipid parameters between drug groups were all 
statistically insignificant (p=0.786) (Table 1) 
 
The overall proportions of patients having desirable, borderline and adverse fasting glucose 
were 83.2%, 13.6%, and 3.2% respectively (Table 2).  Among the four drug classes, the 
proportions of patients having borderline or adverse fasting glucose levels were highest 
among RAS users (16.0%), followed by BB (15.7%), thiazide diuretics (15.0%) and CCB 
(13.0%) (Table 2), but these differences were statistically insignificant (p=0.849). 
 
Factors associated with impaired fasting glucose 
From bivariate analysis between drug class prescribed and the likelihood of patients having 
adverse fasting glucose readings, CCB users were significantly less likely to present with 
above borderline fasting glucose (OR 0.604, 95% C.I. 0.390, 0.933, p=0.022) when compared 
with other drug classes (Table 3).  Otherwise all other comparisons among the four drug 
classes were statistically similar (p=0.278 to 0.986).  However, after controlling for 
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confounding variables by means of multivariate logistic regression, all drug classes were 
statistically similar in presenting with above borderline (p=0.549 to 0.819) and adverse 
(p=0.334 to 0.441) glucose readings.  
 
When compared to young age (<50 years), older patients > 70 years were 2.103 times (95% 
C.I. 1.051, 4.207, p=0.036) more likely to present with above borderline glucose levels (Table 
4). Age was not significantly associated with adverse glucose readings.  While female 
patients were similarly likely to have above borderline glucose readings when compared with 
male patients (p=0.102), they were significantly less likely to have adverse readings (OR 
0.223, 95% C.I. 0.074, 0.674, p=0.008).  Payment status was not significantly associated 
with above borderline and adverse glucose levels.  Patients living in the North district, a 
region with the lowest income level among all districts, were significantly less likely to have 
adverse glucose levels (OR 0.311, 95% C.I. 0.115, 0.841, p=0.021) than residents in Shatin.  
Patients attending different types of clinics were found to have similar odds of having above 
borderline (p=0.179 to 0.414) and adverse fasting glucose levels (p=0.266 to 0.668) (Table 4). 
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Discussion 
Major Findings 
In the present study, we examined the factors associated with impaired fasting glucose among 
Chinese hypertensive patients prescribed a single antihypertensive agent.  No significant 
associations were found between antihypertensive drug class and different extents of impaired 
fasting glucose.  Elderly patients (> 70 years) were more likely to have above borderline 
fasting glucose levels while female patients were less likely to have adverse glucose readings.  
Patients residing in rural areas were less likely to present with adverse glucose readings. 
 
Interpretations of findings and relationship to published literature 
Thiazide diuretics could increase insulin resistance [18], affect glucose utilization [2], 
precipitate overt diabetes [10] and worsen diabetes control [19] but the average rise in blood 
glucose levels in long term resistance trials in diuretic-treated patients was small compared 
with placebo subjects.  Also in large prospective trials unfavorable clinical outcomes have 
not been reported, and the increase in cumulative incidence of new-onset diabetes is by 
approximately 0.6% only [20-25]. 
 
From the ALLHAT study a small increase in serum glucose and a minor rise (3.5%) in the 
absolute risk of developing new-onset diabetes was reported in the thiazide group (11.6%) 
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versus lisinopril (8.1%), but the frequency of CVS events was found to be similar between the 
two drug classes in a five year period [26].  This finding is in echo with the results from the 
Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial 
where diabetic cohorts receiving verapamil, thiazides or β-blockers had similar CVS 
outcomes [27].  In addition, in a large prospective cohort study of 12,500 hypertensive 
patients [28] no increase in the incidence of diabetes was noted with therapeutically low 
doses equivalent to 12.5mg of hydrochlorothiazide.   
 
Another notable finding from ALLHAT revealed that diabetic subjects who received thiazide 
diuretics had coronary heart disease outcomes equal to diabetic subjects who received ACEIs 
(namely lisinopril or amlodipine), yet suffered from fewer strokes or episodes of heart failure 
than the lisinopril group.  In both diabetic and non-diabetic cohorts, less incidence of heart 
failure was reported among patients treated with thiazide diuretics than with amlodipine [26].  
The observation that thiazide use in diabetic patients could be favorable is also supported by 
the majority of studies where diabetic patients had fewer CVS outcomes than non-diabetic 
patients when both groups were prescribed thiazides [29].  Also patients receiving a thiazide 
(chlorthalidone) in the SHEP trial, although having an increased incidence of diabetes, did not 
have a higher rate of CVS events after an average of 14.3 years follow-up [30]. 
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However, it should be noted that current literatures are still mixed in the opinions of using 
thiazides in diabetic patients, where “future troubles should be recognized” [31] particularly 
in newly diagnosed diabetic patients who may have increased risk of heart attack [32].  
Although studies have demonstrated superior efficacy of drugs acting on RAS in preventing 
new-onset type 2 diabetes, namely captopril [33], ramipril [34] and losartan [35], thaizides 
were found to be necessary to reach blood pressure goals in diabetic patients.  The protective 
effect of RAS on occurrence of diabetes has been postulated to be potassium elevation which 
has been recognized to play a crucial role in preventing diabetes [36-37].  Combined use of 
RAS and thiazide diuretics have been recommended in hypertensive patients with family 
history of diabetes or components of metabolic syndrome like obesity, especially in patients 
with stage 2 hypertension [2]. 
 
The present study has reported no association of antihypertensive drug class with any degrees 
of impaired fasting glucose, and is therefore compatible with evidence favoring the use of 
thiazide diuretics in uncomplicated hypertension applicable also to ethnic Chinese patients. 
It was well recognized that ageing is associated with impaired beta cell repair, insulin 
resistance and hence impaired fasting glucose [38] which is consistent with our study findings 
reporting ageing as positively associated with above borderline glucose levels.  The relative 
risks of diabetes for women have been higher than men in all ages [39], and women were also 
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more likely to have abnormal glucose regulation [40].  The present study, on the contrary, 
demonstrated that female is at lower risk of having adverse glucose readings.   
 
Hyperglycaemia is a concentration-dependent predictor of long-term mortality after a 
coronary event, and this predictive value is stronger in men than women [41].    But risk of 
coronary heart disease in women may be elevated at a lower glucose level than for men [42], 
consistent with other findings that diabetes was reported as a greater risk factor for 
cardiovascular diseases in women than in men [43-44].  Therefore in the present study, the 
lower odds of having impaired fasting glucose in women than men should be interpreted in 
the light of the greater risk of incidence of CVS diseases among diabetic women than diabetic 
men. 
 
Patients residing in more rural areas, namely the North district, may have more healthy 
dietary lifestyles.  No studies have evaluated the association between socioeconomic status 
and elevated fasting glucose, and this area remains to be explored. 
  
Strengths and weaknesses of current study 
The present study adopted an observational design including only antihypertensive drug naïve 
patients newly received an antihypertensive agent without oral hypoglycemic agents or 
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insulin use, concomitant cardiovascular disorders or other medical conditions which could 
confound choice of prescriptions.  The periods where glucose levels were checked after the 
prescription were approximately 7 weeks which were statistically similar among the four drug 
groups.  In conjunction with our fairly large sample size we believed this study reflects 
real-world clinical practice.  Also our patients had similar sociodemographic characteristics 
compared to the entire population of Hong Kong [21] making it more likely that our findings 
are generalizable. 
 
However, some limitations of this study should be discussed.  First, we do not have a 
baseline glucose profile which could act as reference levels for comparisons of levels before 
and after drug prescriptions, and this study only evaluated a short time frame of 
approximately seven weeks, a period which might not suffice metabolic effects to take place.  
Also, we regarded the absence of ICPC coding as meaning the absence of the relevant 
condition, but in a previous validation study of this clinical database [16] it was shown that 
patients coded with K86 (uncomplicated hypertension) only were likely to be suffering from 
uncomplicated hypertension as the single disease entity without other concomitant medical 
conditions.  In addition, age, gender and district of residence were associated with either 
above borderline or adverse glucose readings (but not both), which might weaken the 
conclusion drawn.  Some confounders like smoking and risk factors for developing impaired 
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glucose tolerance like obesity could not be controlled for due to lack of relevant data, and the 
absence of oral glucose tolerance tests would mean the diagnosis of impaired glucose 
tolerance could not be ascertained.  Finally, our study cannot prove causative relationships 
between the predictor variables and glucose profiles, which could only be addressed by a 
prospective cohort design.   
 
Implications for policy and practice 
This study evaluated age, gender, socioeconomic factors, types of clinic services and the 
antihypertensive drug classes as associated factors of impaired fasting glucose in Chinese 
patients with uncomplicated hypertension.  Physicians may practice higher caution in 
managing hypertensive patients with these associated factors at higher risk of impaired fasting 
glucose, implying a greater need for more regular screening of glucose profiles, especially 
among older patients, males, and those residing in more urbanized areas.  Since the 
antihypertensive drug classes were not shown to be associated with impaired glucose levels, 
the use of thiazide as a first-line agent in patients with uncomplicated hypertension could be 
justified in ethnic Chinese according to recommendations from most international guidelines.   
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Conclusion 
We examined the independent factors associated with the presentation of impaired fasting 
glucose among 1,218 hypertensive patients newly prescribed a single antihypertensive agent.  
Age, gender and district of residence were significant independent predictors of impaired 
fasting glucose among Chinese hypertensive patients while antihypertensive drug classes 
were not associated with elevated glucose readings.  Physicians could use these independent 
factors as a reference for more meticulous monitoring of glucose levels among hypertensive 
Chinese patients presented with these associated factors. 
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Table 1: Patient characteristics (N=1,218) 
 β-blockers 
(n=307) 
Thiazide  
(n=196) 
CCBs 
(n=322) 
RAS 
(n=55) 
Others* 
(n=338) 
p value 
Age (years)
<50 
50-59 
60-69 
>70 
 
85 (27.7) 
113 (36.8) 
59 (19.2) 
50 (16.3) 
 
38 (19.4) 
62 (31.6) 
51 (26.0) 
45 (23.0) 
 
74 (23.0) 
87 (27.0) 
70 (21.7) 
91 (28.3) 
 
9 (16.4) 
22 (40.0) 
11 (20.0) 
13 (23.6) 
 
58 (17.2) 
84 (24.9) 
77 (22.8) 
119 (35.2) 
 
<0.001 
Mean Age 
(SD)  
(95% CI) 
56.96 
(11.67) 
(55.651,58.27) 
60.14 
(11.37) 
(58.54, 61.74)  
60.80 
(13.21) 
(59.36, 62.25) 
60.02 
(12.83) 
(56.55, 63.49) 
63.30 
(13.42) 
(61.87, 64.74) 
 
<0.001 
Gender (no./%) 
Female 
Male 
 
200 (65.1) 
107 (34.9) 
 
124 (63.3) 
72 (36.7) 
 
168 (52.2) 
154 (47.8) 
 
33 (60.0) 
22 (40.0) 
 
189 (55.9) 
149 (44.1) 
 
0.008 
Payment  
Fee-waivers 
Payers 
 
107 (34.9) 
200 (65.1) 
 
68 (34.7) 
128 (65.3) 
 
107 (33.2) 
215 (66.8) 
 
17 (30.9) 
38 (69.1) 
 
96 (28.4) 
242 (71.6) 
 
0.415 
District of 
residence 
Shatin 
Taipo 
Northern 
Others 
 
 
85 (27.7) 
31 (10.1) 
161 (52.8) 
30 (9.4) 
 
 
44 (22.4) 
13 (6.6) 
127 (64.8) 
12 (6.1) 
 
 
84 (26.1) 
52 (16.1) 
169 (52.5) 
17 (5.3) 
 
 
12 (21.8) 
5 (9.1) 
34 (61.8) 
4 (7.3) 
 
 
135 (39.9) 
37 (10.9) 
134 (39.6) 
32 (9.5) 
 
 
<0.001 
Service type 
General 
FMSC 
Staff clinic 
 
264 (86.0) 
29 (9.4) 
14 (4.6) 
 
179 (91.3) 
7 (3.6) 
10 (5.1) 
 
288 (89.4) 
27 (8.4) 
7 (2.2) 
 
48 (87.3) 
4 (7.3) 
3 (5.5) 
 
275 (81.4) 
56 (16.6) 
7 (2.1) 
 
<0.001 
Glucose 
Profile 
(mean + 95% CI) 
5.42 
(5.34, 5.51) 
5.48 
(5.38, 5.59) 
5.46 
(5.37, 5.54) 
5.41 
(5.20, 5.61) 
5.60 
(5.52, 5.68) 
0.786 
Period from drug 
prescription to 
blood taking 
(weeks) 
Median (IQR) 
7.43 
(5.86, 10.00) 
7.00 
(5.18, 8.96) 
7.79 
(5.57, 10.32) 
6.71 
(5.00, 10.00) 
8.00 
(6.00, 12.00) 
0.054** 
 
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system, IQR: Inter-quartile Ranges) 
*Others refer to drug classes including α-blockers, polytherapy, combination therapy, and Misc classes 
**Refers to comparison among four drug groups: β-blockers, thiazide diuretics, CCB, RAS) 
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Table 2: Patterns of glucose profiles by drug group (No./%) 
 
 β-blockers 
 
Thiazide 
 
CCBs 
 
RAS 
 
Others 
 
P 
(χ2) 
Glucose (mmol/l) 
 
Desirable (< 6.0) 
Borderline (6.1-6.9) 
Adverse (> 7.0) 
(n=280) 
 
236 (84.3) 
35 (12.5) 
9 (3.2) 
(n=180) 
 
153 (85.0) 
22 (12.2) 
5 (2.8) 
(n=291) 
 
253 (86.9) 
28 (9.6) 
10 (3.4) 
(n=50) 
 
42 (84.0) 
5 (10.0) 
3 (6.0) 
(n=296) 
 
229 (77.4) 
59 (19.9) 
8 (2.7) 
 
 
0.849 
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system. 
Glucose levels for desirable: < 6.0 mmol/l, borderline: 6.1-6.9 mmol/l; adverse: > 7.0 mmol/l) 
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Table 3  The crude hazard ratios of having above borderline and adverse glucose 
profiles for each antihypertensive drug group 
 
 Bivariate Analysis 
Crude Odds Ratios for 
above borderline results  
(95 % C.I.) 
(> 6.1 mmol/l) 
p value Bivariate Analysis 
Crude Odds Ratios for 
adverse results (95 % 
C.I.) 
(> 7.0 mmol/l) 
p value 
(1). β-blockers 
 
0.881 (0.586, 1.323) 
 
0.540 
 
0.993 (0.459, 2.150) 0.986 
(2). Thiazide 
Diuretics 
 
0.860 (0.530, 1.397) 
 
0.543 
 
0.828 (0.316, 2.168) 0.700 
(3). CCB  
 
0.604 (0.390, 0.933) 
 
0.022 
 
1.043 (0.494, 2.204) 0.911 
(4). RAS 
 
0.720 (0.280, 1.850) 
 
0.493 
 
1.944 (0.572, 6.607) 0.278 
 
(CCB: Calcium channel blockers; RAS: drugs acting on the rennin angiotensin system. Glucose 
levels for desirable: < 6.0 mmol/l, above borderline: > 6.1 mmol/l; adverse: > 7.0 mmol/l.  The 
desirable group was used as the reference) 
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Table 4  Factors associated with hyperglycemia with above borderline and 
adverse readings* 
Above Borderline readings Adverse readings   
Odds Ratios  
(95% CI) 
p Odds Ratios  
(95% CI) 
p 
Age (years)
<50 
50-59 
60-69 
>70 
 
1.0 (ref) 
1.249 (0.648, 2.408) 
1.344 (0.654, 2.759) 
2.103 (1.051, 4.207) 
 
 
0.506 
0.421 
0.036 
 
1.0 (ref) 
1.776 (0.533, 5.919) 
0.784 (0.167, 3.685) 
1.359 (0.372, 4.962) 
 
 
0.349 
0.758 
0.643 
Gender 
Male 
Female 
 
1.0 (ref) 
1.464 (0.927, 2.313) 
 
 
0.102 
 
1.0 (ref) 
0.223 (0.074, 0.674) 
 
 
0.008 
Payment 
status 
Fee waiver 
Fee payers 
 
 
1.0 (ref) 
1.328 (0.789, 2.236) 
 
 
 
0.286 
 
 
1.0 (ref) 
0.759 (0.320, 1.798) 
 
 
 
0.530 
District of 
residence 
Shatin 
Taipo 
North 
Others 
 
 
1.0 (ref) 
0.967 (0.433, 2.156) 
0.707 (0.392, 1.273) 
0.909 (0.363, 2.279) 
 
 
 
0.934 
0.248 
0.839 
 
 
1.0 (ref) 
1.676 (0.588, 4.778) 
0.311 (0.115, 0.841) 
N/A 
 
 
 
0.334 
0.021 
N/A 
Clinics 
GOPC 
FMSC  
Staff clinics 
 
1.0 (ref) 
0.652 (0.234, 1.818) 
2.071 (0.717, 5.984) 
 
 
0.414 
0.179 
 
 
0.299 (0.036, 2.507) 
0.614 (0.066, 5.732) 
 
 
0.266 
0.668 
Drug class 
RAS 
β-blockers 
Thiazide 
CCB 
 
1.0 (ref) 
1.360 (0.497, 3.721) 
1.252 (0.443, 3.537) 
0.888 (0.320, 2.463) 
 
 
0.549 
0.672 
0.819 
 
1.0 (ref) 
0.518 (0.125, 2.151) 
0.466 (0.099, 2.190) 
0.575 (0.140, 2.353) 
 
 
0.365 
0.334 
0.441 
(C.I: confidence intervals, GOPC: General Out-patient clinics, FMSC: Family Medicine Specialist Clinics.  
RAS: drugs acting on the renin angiotensin system; CCB: Calcium channel blockers.   
*Above borderline readings were defined as fasting glucose > 6.1 mmol/l; adverse readings as fasting 
glucose > 7.0 mmol/l.  All adjusted Odds Ratio were adjusted for age, gender, payment status, district of 
residence, service types of attended clinics and other drug classes as listed in table 
N/A: No patients presented with adverse readings) 
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